CD8A and neoplasm: To study the impact of AC484 treatment on CD8+ T cell exhaustion, we sorted tumour-infiltrating SLAMF6+ (progenitor exhausted) and TIM-3+ (terminally exhausted) CD8+ T cells from untreated mice, AC484-treated mice and anti-PD-1-treated mice, and performed bulk RNA-seq and ATAC–seq (Extended Data Fig. 7a,b).